Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026

Spyre Therapeutics (NASDAQ:SYRE) is 1 of the 17 biotechnology stocks with much than 50% upside.

As of the adjacent of play connected February 12, statement sentiment astir Spyre Therapeutics (NASDAQ:SYRE) was powerfully bullish. The banal had received sum from 7 analysts, each of whom assigned Buy ratings. It has a projected median 1-year terms people of $57.86, offering an upside of much than 66%.

Copyright: mikkolem / 123RF Stock Photo

On January 22, Spyre Therapeutics (NASDAQ:SYRE) announced plans for 2026, wherever it volition prioritize six POC readouts. The institution mentioned that its SKYLINE ulcerative colitis proceedings has seen SPY001 enrollment implicit up of schedule, accelerating Part A readouts to sometime successful the 2nd quarter. The SKYWAY handbasket proceedings connected rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis remains connected way for fourth-quarter readouts successful 2026. Financially, $783 cardinal successful pro forma cash, currency equivalents, and marketable securities arsenic of September 30, 2025, provides a runway done the 2nd fractional of 2028. The institution besides appointed Kate Tansey Chevlen arsenic Chief Commercial Officer, who is simply a seasoned biopharma commercialized leader.

Spyre Therapeutics (NASDAQ:SYRE) is simply a clinical-stage biotechnology institution processing precocious antibody therapeutics for patients with inflammatory bowel illness (IBD). The institution focuses connected next-gen cures for conditions specified arsenic ulcerative colitis and Crohn’s disease. Its existent pipeline includes SPY001, SPY002, SPY003, and immoderate operation therapies.

While we admit the imaginable of TSLA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.